Table 1.
Baseline characteristics of 263 resectable cholangiocarcinoma patients n (%)
| Age, yr | |
| mean ± SD | 59.0 ± 8.9 |
| Range | 35-80 |
| Male | 181 (69.6) |
| DM | 19 (6.5) |
| BMI (mean ± SD), kg/m2 | |
| < 18.5 | 23 ± 8.7 |
| 18.5-22.9 | 127 ± 48.3 |
| 23-24.9 | 47 ± 17.9 |
| 25-29.9 | 48 ± 18.3 |
| ≥ 30 | 13 ± 4.9 |
| Not available | 5 ± 1.9 |
| Clinical manifestation | |
| Abdominal pain | 164 (62.4) |
| Jaundice | 54 (20.5) |
| Fever | 6 (2.3) |
| Cholangitis | 4 (1.5) |
| Weight loss | 1 (0.4) |
| Asymptomatic | 17 (6.5) |
| Hepatomegaly | 153 (58.2) |
| Total bilirubin (mg/dL) | |
| < 10 | 213 (81.0) |
| ≥ 10 | 50 (19.0) |
| Cholesterol (mg/dL) | |
| < 200 | 168 (63.9) |
| ≥ 200 | 95 (36.1) |
| Albumin (g/dL) | |
| < 3 | 42 (16.0) |
| ≥ 3 | 220 (83.7) |
| ALT (U/L) | |
| < 30 | 46 (17.5) |
| ≥ 30 | 151 (82.5) |
| AST (U/L) | |
| < 30 | 25 (9.5) |
| ≥ 30 | 238 (90.5) |
| ALP (U/L) | |
| < 100 | 82 (31.2) |
| ≥ 100 | 180 (68.5) |
| CA 19-9 (U/mL) | |
| < 35 | 108 (41.1) |
| ≥ 35 | 148 (56.3) |
| CEA (ng/mL) | |
| < 2.5 | 65 (24.7) |
| ≥ 2.5 | 183 (69.6) |
| Receiving adjuvant chemotherapy | |
| Yes | 138 (52.5) |
| No | 125 (47.5) |
CA 19-9: Carbohydrate antigen 19-9; CEA: Carcinoembryonic antigen; ALT: Alanine transaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; BMI: Body mass index; DM: Diabetes mellitus.